Puretech Health Plc (PRTC) Quarterly Income Statement

Quarterly · GAAP · USD millions
Access PRTC Annual Income Statement →
By examining income statement figures across successive periods, users can identify shifts in Puretech Health Plc's profitability and expense structure.
Quarterly Report, GAAP in USD millions
ITEM
(Dec 31 2025)
Q4 2025
0 0 0 (Dec 31 2024)
Revenues
Revenue From Contracts With Customers4.66
Total Revenue4.66
Costs & Expenses
Gross Profit4.66
Selling, Administration, Marketing46.62
Research and Development Expense56.57
OtherOperating Income Expense0.00
Total operating costs including COS103.19
Operating income / -loss-98.53
Net Interest (-)Expense / Income0.00
Other loss / -income1.23
Total costs & expenses115.59
Income & Taxes
Income / -loss before income taxes-110.93
Income taxes expenses / -benefit-0.84
Income after income taxes-110.08
Net income / -loss of other equity0.00
Income / -loss from continuing operations-110.08
Non-controlling interests-0.35
Net income / -loss-110.08
Income / -loss to shareholder-109.74
EBIT-110.93
EBITD-110.93
EBITDA-110.93
Earnings Per Share
Basic EPS (excl. extra items)0.00
Basic Net EPS0.00
Diluted Net EPS0.00
4 historic quarters locked

Sign in to unlock the full Puretech Health Plc income statement history.

About PRTC Quarterly Income Statement

What this statement shows

This page presents issuer-reported income statement data, detailing revenue, operating costs, expenses, and earnings as disclosed in SEC 10-Q filings and standardized by CSIMarket. The income statement reflects operating performance over a reporting period rather than financial position at a single date.

Revenue and expense treatment

Revenue and expense items are aligned to support period-to-period comparability. Operating and non-operating items, interest, and income taxes are classified based on issuer disclosures and XBRL tagging.

Source & verification

  • Source: SEC 10-Q filings
  • Filed with the SEC: n/a

Income statement figures represent operating results for each reporting period and may be revised in subsequent filings.